FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085366166> ?p ?o ?g. }

• W2085366166 abstract "Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration function, containing in slope of 1/serum creatinine (1/SCr) vs. time in a phase II clinical trial.We describe the design of the phase IIb/III trial of TRK-100STP, CASSIOPEIR (CRF Asian Study with Oral PGI2 derivative for Evaluating Improvement of Renal function) conducted in approximately 160 centers in China, Hong Kong, Japan, Malaysia, Republic of Korea, Taiwan, and Thailand. A total of 750 patients (n = 250 per group) with primary glomerular disease or nephrosclerosis were planned to be enrolled. Patients were randomized into one of three treatment groups in a double-bind, placebo-controlled manner: TRK-100STP 60 μg b.i.d.; TRK-100STP 120 μg b.i.d.; or placebo. The treatment period is planned to last 2 to 4 years. The primary efficacy endpoint is the renal composite endpoint including doubling of SCr and ESRD (dialysis induction, renal transplantation, or increase in SCr to ≥ 6.0 mg/dL).This trial targeting CKD patients is designed to (a) demonstrate the superiority of TRK-100STP over placebo using renal composite endpoints, (b) determine the recommended clinical dose, and (c) assess the safety of TRK-100STP in this population and setting.ClinicalTrials.gov Identifier: NCT01090037." @default.
• W2085366166 created "2016-06-24" @default.
• W2085366166 creator A5009147715 @default.
• W2085366166 creator A5014957707 @default.
• W2085366166 creator A5016397296 @default.
• W2085366166 creator A5036590014 @default.
• W2085366166 creator A5045335722 @default.
• W2085366166 creator A5047586418 @default.
• W2085366166 creator A5068802392 @default.
• W2085366166 creator A5071531810 @default.
• W2085366166 creator A5080266991 @default.
• W2085366166 date "2014-09-19" @default.
• W2085366166 modified "2023-10-09" @default.
• W2085366166 title "A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design" @default.
• W2085366166 cites W1922859388 @default.
• W2085366166 cites W1988922477 @default.
• W2085366166 cites W1989951741 @default.
• W2085366166 cites W2001544028 @default.
• W2085366166 cites W2011002621 @default.
• W2085366166 cites W2021403302 @default.
• W2085366166 cites W2021915768 @default.
• W2085366166 cites W2024097598 @default.
• W2085366166 cites W2038292697 @default.
• W2085366166 cites W2043537788 @default.
• W2085366166 cites W2046566239 @default.
• W2085366166 cites W2047335781 @default.
• W2085366166 cites W2056309627 @default.
• W2085366166 cites W2059313452 @default.
• W2085366166 cites W2064798139 @default.
• W2085366166 cites W2068456857 @default.
• W2085366166 cites W2070277165 @default.
• W2085366166 cites W2076261384 @default.
• W2085366166 cites W2084414030 @default.
• W2085366166 cites W2085673497 @default.
• W2085366166 cites W2109312341 @default.
• W2085366166 cites W2112948259 @default.
• W2085366166 cites W2129859917 @default.
• W2085366166 cites W2138862624 @default.
• W2085366166 cites W2140235554 @default.
• W2085366166 cites W2147363374 @default.
• W2085366166 cites W2152798629 @default.
• W2085366166 cites W2158458517 @default.
• W2085366166 cites W2162069666 @default.
• W2085366166 cites W2162368776 @default.
• W2085366166 cites W2321522617 @default.
• W2085366166 cites W328744082 @default.
• W2085366166 doi "https://doi.org/10.1186/1471-2369-15-153" @default.
• W2085366166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4181382" @default.
• W2085366166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25233856" @default.
• W2085366166 hasPublicationYear "2014" @default.
• W2085366166 type Work @default.
• W2085366166 sameAs 2085366166 @default.
• W2085366166 citedByCount "6" @default.
• W2085366166 countsByYear W20853661662015 @default.
• W2085366166 countsByYear W20853661662018 @default.
• W2085366166 countsByYear W20853661662019 @default.
• W2085366166 countsByYear W20853661662020 @default.
• W2085366166 countsByYear W20853661662021 @default.
• W2085366166 countsByYear W20853661662022 @default.
• W2085366166 crossrefType "journal-article" @default.
• W2085366166 hasAuthorship W2085366166A5009147715 @default.
• W2085366166 hasAuthorship W2085366166A5014957707 @default.
• W2085366166 hasAuthorship W2085366166A5016397296 @default.
• W2085366166 hasAuthorship W2085366166A5036590014 @default.
• W2085366166 hasAuthorship W2085366166A5045335722 @default.
• W2085366166 hasAuthorship W2085366166A5047586418 @default.
• W2085366166 hasAuthorship W2085366166A5068802392 @default.
• W2085366166 hasAuthorship W2085366166A5071531810 @default.
• W2085366166 hasAuthorship W2085366166A5080266991 @default.
• W2085366166 hasBestOaLocation W20853661661 @default.
• W2085366166 hasConcept C126322002 @default.
• W2085366166 hasConcept C134139212 @default.
• W2085366166 hasConcept C142724271 @default.
• W2085366166 hasConcept C159641895 @default.
• W2085366166 hasConcept C170493617 @default.
• W2085366166 hasConcept C203092338 @default.
• W2085366166 hasConcept C204787440 @default.
• W2085366166 hasConcept C27081682 @default.
• W2085366166 hasConcept C2778653478 @default.
• W2085366166 hasConcept C2908647359 @default.
• W2085366166 hasConcept C535046627 @default.
• W2085366166 hasConcept C54847362 @default.
• W2085366166 hasConcept C71924100 @default.
• W2085366166 hasConcept C90924648 @default.
• W2085366166 hasConcept C92020748 @default.
• W2085366166 hasConcept C99454951 @default.
• W2085366166 hasConceptScore W2085366166C126322002 @default.
• W2085366166 hasConceptScore W2085366166C134139212 @default.
• W2085366166 hasConceptScore W2085366166C142724271 @default.
• W2085366166 hasConceptScore W2085366166C159641895 @default.
• W2085366166 hasConceptScore W2085366166C170493617 @default.
• W2085366166 hasConceptScore W2085366166C203092338 @default.
• W2085366166 hasConceptScore W2085366166C204787440 @default.
• W2085366166 hasConceptScore W2085366166C27081682 @default.
• W2085366166 hasConceptScore W2085366166C2778653478 @default.
• W2085366166 hasConceptScore W2085366166C2908647359 @default.
• W2085366166 hasConceptScore W2085366166C535046627 @default.
• W2085366166 hasConceptScore W2085366166C54847362 @default.
• W2085366166 hasConceptScore W2085366166C71924100 @default.
• W2085366166 hasConceptScore W2085366166C90924648 @default.

• next